Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P48736
UPID:
PK3CG_HUMAN
Alternative names:
Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; Phosphoinositide-3-kinase catalytic gamma polypeptide; Serine/threonine protein kinase PIK3CG; p120-PI3K
Alternative UPACC:
P48736; A4D0Q6; Q8IV23; Q9BZC8
Background:
The Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, also known as PIK3CG, plays a pivotal role in cellular processes including growth, survival, proliferation, and motility. It is crucial in immune responses, modulating leukocyte chemotaxis, and involved in the development and migration of natural killer cells and T-lymphocytes. PIK3CG's kinase activity influences cardiac contractility and contributes to pathological cardiac hypertrophy.
Therapeutic significance:
Given its involvement in Immunodeficiency 97 with autoinflammation, targeting PIK3CG presents a promising avenue for therapeutic intervention. Understanding the role of PIK3CG could open doors to potential therapeutic strategies, particularly in treating immune-related disorders and modulating cardiac functions.